HengRui goes pivotal in KRAS G12D
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
ESMO 2025 – Padcev plus Keytruda sets the perioperative bar
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
ESMO 2025 preview – Astellas's third Claudin18.2 shot
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
AACR 2025 – Revolution shows lung promise
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
